Table 1 Clinical characteristics at the time of the first and second liver biopsies, of 36 patients with NAFLD free of hepatocellular carcinoma
First biopsy | Second biopsy | |
|---|---|---|
Demographic data | ||
Number of patients | 36 | 36 |
Gender (Male/Female) | 20/16 | 20/16 |
Histological findings | ||
Steatosis (0/1/2/3) | 0/8/20/8 | 1/15/15/5 |
Lobular inflammation (0/1/2/3) | 4/14/13/5 | 2/20/14/0 |
Ballooning (0/1/2) | 2/21/13 | 4/23/9 |
Stage (0/1/2/3/4) | 5/13/6/11/1 | 2/16/5/12/1 |
Matteoni classification (type 1/2/3/4) | 1/1/3/31 | 0/1/1/33 |
NAFLD activity score (≤2/3, 4/≥5) | 2/12/22 | 4/16/16 |
Clinical parameters | ||
Age (years) | 49 (24-69) | 59 (26-70) |
Body mass index (kg/m2) | 25.6 (20.5-36.5) | 25.5 (19.1-33.6) |
Serum aspartate aminotransferase (IU/l) | 61 (19-152) | 37 (14-132) |
Serum alanine aminotransferase (IU/l) | 104 (28-303) | 49 (8-304) |
Gamma-glutamyl transpeptidase (IU/l) | 65 (17-505) | 43 (9-359) |
Serum albumin (g/dl) | 4.1 (3.4-4.9) | 4.0 (2.8-4.5) |
Platelet count (×103/mm3) | 210 (117-389) | 207 (111-296) |
Fasting plasma glucose (mg/dl) | 94 (65-142) | 106 (73-278) |
Uric acid (mg/dl) | 6.0 (1.8-9.5) | 5.9 (1.5-9.2) |
Total cholesterol (mg/dl) | 209 (130-290) | 202 (131-270) |
Triglycerides (mg/dl) | 137 (62-254) | 131 (54-295) |
High-density lipoprotein cholesterol (mg/dl) | 44 (29-85) | 45 (27-73) |
Low-density lipoprotein cholesterol (mg/dl) | 129 (66-205) | 123 (64-175) |
Non high-density lipoprotein cholesterol (mg/dl) | 162 (95-228) | 150 (95-219) |
Serum ferritin (μg/l) | 265 (<10-1,472) | 202 (13-1,018) |
Hyaluronic acid (μg/l) | 34 (8-561) | 30 (0-222) |
Serum miR-122 (fold change) | 1.03 (0.13-7.63) | 0.66 (0.03-7.65) |